Across TCGA pan-cancer cohorts, RIPK4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RIPK4 data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RIPK4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RIPK4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where RIPK4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.322	0.734	<.001	37	view →
PDAC	DFS	Tertile	All	0.724	0.236	.012	12	view →
HNSC	OS	Median	II,III,IV	0.830	0.584	.031	5	view →
CCRCC	OS	Median	III,IV	1.000	0.289	.022	3	view →
LSCC	DFS	Tertile	All	0.866	0.296	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RIPK4 tumor-vs-normal RNA expression · all RIPK4 data types